Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07391774 · ClinicalTrials.gov registry record · Phase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
A Phase 3 study, sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,978
- Enrollment target
NCT07391774: Recruiting Phase 3 study, sponsored by National Cancer Institute (NCI).
NCT07391774 is a Phase 3 study that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,978 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07391774, a Phase 3 study, is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,978 participants
- Enrollment target
Study Summary
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy, with letrozole, anastrozole or exemestane, lowers the amount of estrogen made by the body. This may help stop the growth of tumor cells that need estrogen to grow. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Hormone therapy plus ribociclib may work as well as chemotherapy followed by hormone therapy plus ribociclib for the treatment of high anatomic stage breast cancer with low recurrence risk.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography
- PROCEDURE Bone Scan
- DRUG Anastrozole
- DRUG Chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,978 participants |
| Start Date | 2027-02-14 |
| Est. Completion | 2029-07-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07391774
The ClinicalTrials.gov registry entry for NCT07391774 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,978 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT07391774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07391774 about?
NCT07391774 is a clinical study titled "Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial". This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the cancer returning (low risk recurrence). Ribociclib may stop the growth ...
What is the current status of trial NCT07391774?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,978 participants. The study started on 2027-02-14. Estimated completion is 2029-07-31.
What interventions are being tested in trial NCT07391774?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Bone Scan (PROCEDURE), Anastrozole (DRUG), Chemotherapy (DRUG).
Who is sponsoring clinical trial NCT07391774?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.